Off-pathway α-synuclein oligomers seem to alter α-synuclein turnover in a cell model but lack seeding capability in vivo

Amyloid

Volumn 20, Issue 4, 2013, Pages 233-244

  Fagerqvist, Therese ^a   Näsström, Thomas ^a   Ihse, Elisabet ^a   Lindström, Veronica ^a   Sahlin, Charlotte ^a   Fangmark Tucker, Stina M ^b   Kasaryan, Alex ^b   Karlsson, Mikael ^c   Nikolajeff, Fredrik ^c   Schell, Heinrich ^d   Outeiro, Tiago F ^e   Kahle, Philipp J ^d   Lannfelt, Lars ^a   Ingelsson, Martin ^a   Bergström, Joakim ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b BioArctic Neuroscience   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Aggregation; Alpha synuclein; Oligomers; Parkinson's disease; Seeding

Indexed keywords

ALDEHYDE DERIVATIVE; ALPHA SYNUCLEIN; OLIGOMER; PROTEINASE K; THIOFLAVINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MALE; MOLECULAR MODEL; MOUSE; NEOCORTEX; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; TRANSGENIC MOUSE;

ALDEHYDES; ALPHA-SYNUCLEIN; ANIMALS; BRAIN; CELL LINE, TUMOR; HUMANS; MICE; MICE, TRANSGENIC; MICROSCOPY, ATOMIC FORCE; PARKINSON DISEASE;

EID: 84888053160     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2013.835726     Document Type: Article

References (39)

1. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388: 839-40.
2. Clayton DF, George JM. Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 1999;58:120-9.
3. Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010;329:1663-7.
4. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010;65:66-79.
5. Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S. A pathologic cascade leading to synaptic dysfunction in alphasynuclein-induced neurodegeneration. J Neurosci 2010;30: 8083-95.
6. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury Jr PT. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 2000;97:571-6.
7. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003;302:841.
8. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, Agid Y, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004;364: 1169-71.
9. Uversky VN, Li J, Fink AL. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem 2001; 276:10737-44.
10. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 1999;274:19509-12.
11. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008;14:504-6.
12. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008;14:501-3.
13. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009;106:13010-5.
14. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012;338:949-53.
15. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological alphasynuclein initiates a rapidly progressive neurodegenerative alphasynucleinopathy in mice. J Exp Med 2012;209:975-86.
16. Danzer KM, Krebs SK, Wolff M, Birk G, Hengerer B. Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J Neurochem 2009;111: 192-203.
17. Luk KC, Song C, O'Brien P, Stieber A, Branch JR, Brunden KR, Trojanowski JQ, et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A 2009;106:20051-6.
18. Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 2007;27: 9220-32.
19. Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, Carvalho F, Hyman BT, et al. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One 2008;3:e1867.
20. Diogenes MJ, Dias RB, Rombo DM, Miranda HV, Maiolino F, Guerreiro P, Nasstrom T, et al. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci 2012;32:11750-62.
21. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 2008;15:558-66.
22. Qin Z, Hu D, Han S, Reaney SH, Di Monte DA, Fink AL. Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J Biol Chem 2007;282:5862-70.
23. Lin D, Lee HG, Liu Q, Perry G, Smith MA, Sayre LM. 4-Oxo-2-nonenal is both more neurotoxic and more protein reactive than 4-hydroxy-2-nonenal. Chem Res Toxicol 2005;18: 1219-31.
24. Nasstrom T, Fagerqvist T, Barbu M, Karlsson M, Nikolajeff F, Kasrayan A, Ekberg M, et al. The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of alpha-synuclein oligomers with distinct biochemical, morphological, and functional properties. Free Radic Biol Med 2011;50: 428-37.
25. Nasstrom T, Wahlberg T, Karlsson M, Nikolajeff F, Lannfelt L, Ingelsson M, Bergstrom J. The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers. Biochem Biophys Res Commun 2009;378: 872-6.
26. Bae EJ, Ho DH, Park E, Jung JW, Cho K, Hong JH, Lee HJ, et al. Lipid peroxidation product 4-hydroxy-2-nonenal promotes seedingcapable oligomer formation and cell-to-cell transfer of alphasynuclein. Antioxid Redox Signal 2013;18:770-83.
27. Zhu M, Rajamani S, Kaylor J, Han S, Zhou F, Fink AL. The flavonoid baicalein inhibits fibrillation of alphasynuclein and disaggregates existing fibrils. J Biol Chem 2004; 279:26846-57.
28. LeVine H. Thioflavine T interaction with amyloid-b-sheet structures. Amyloid: Int J Exp Clin Invest 1995.
29. Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Muller V, et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest 2002;110:1429-39.
30. Freichel C, Neumann M, Ballard T, Muller V, Woolley M, Ozmen L, Borroni E, et al. Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol Aging 2007;28:1421-35.
31. Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Schindzielorz A, Okochi M, et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci 2000;20: 6365-73.
32. Schulz-Schaeffer WJ, Tschoke S, Kranefuss N, Drose W, Hause-Reitner D, Giese A, Groschup MH, et al. The paraffin-embedded tissue blot detects PrP(Sc) early in the incubation time in prion diseases. Am J Pathol 2000;156:51-6.
33. Cappai R, Leck SL, Tew DJ, Williamson NA, Smith DP, Galatis D, Sharples RA, et al. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J 2005;19:1377-9.
34. Hong DP, Fink AL, Uversky VN. Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein. J Mol Biol 2008;383:214-23.
35. Pham CL, Leong SL, Ali FE, Kenche VB, Hill AF, Gras SL, Barnham KJ, et al. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner. J Mol Biol 2009;387:771-85.
36. Lee HJ, Suk JE, Bae EJ, Lee SJ. Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem Biophys Res Commun 2008;372:423-8.
37. Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuronspecific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 1988;8:2804-15.
38. Colla E, Jensen PH, Pletnikova O, Troncoso JC, Glabe C, Lee MK. Accumulation of toxic alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy in vivo. J Neurosci 2012;32:3301-5.
39. Fagerqvist T, Lindstrom V, Nordstrom E, Lord A, Tucker SM, Su X, Sahlin C, et al. Monoclonal antibodies selective for alpha-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and alpha-synuclein transgenic mice with the disease-causing A30P mutation. J Neurochem 2013;126:131-44.